Piramal Pharma Limited — Others, 14-05-2025: Appointment

Piramal Pharma Limited has announced a board meeting on the financial results for the quarter and half-year. The Board approved audited standalone revenue of Rs 5,493 Cr and consolidated revenue of Rs 9,151 Cr for the year, with standalone net profit at Rs 691 Cr and consolidated net profit at Rs 91 Cr. A final dividend of Rs 0.14 per share has been proposed. Leadership changes include the resignation of Mr. Neeraj Bharadwaj as Non-Executive Director and appointment of Mr. Amit Jain. Mr. Jairaj Purandare was re-appointed as Independent Director. An impairment charge of Rs 44.75 Cr was recognized in a subsidiary, and Rs 32.27 Cr provisions were made related to an ongoing supplier insolvency. Auditors issued unqualified opinions.